Feb 18 () - Contract drug developer Charles River Laboratories on Wednesday forecast annual profit above Wall Street ...

EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug. | EIR Biopharma is hoping to bring in $17.

Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” ...

Get a closer look at the biotech ophthalmology landscape to discover exactly how companies are approaching the treatment of eye diseases.

Here are the latest biotech industry updates: introducing new platforms for SPR, RNA-seq libraries and DNA extraction.

Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks.

And the presence of the Barcelona Science Park, which is the first science park in Spain that is home to three research institutes and more than 70 companies, make the city a viable location for ...

Chinese pharmaceutical companies that as a group chalked up record outbound licensing agreements with international industry ...

Viking Therapeutics (VKTX +4.90%) is aiming to join one of the biggest growth industries of the times: the weight loss drug ...

Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and ...

Peptris will use the capital raised to advance its existing programmes toward clinical readiness and to expand its pipeline ...